Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01293123 · ClinicalTrials.gov registry record · NA
Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals
A NA study, sponsored by University of California, San Diego.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT01293123: Clinical Trial NA study, sponsored by University of California, San Diego.
NCT01293123 is a NA study that was terminated before completion, run by University of California, San Diego. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01293123, a NA study, was terminated before completion, sponsored by University of California, San Diego.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
The primary aim of this study is to determine the effects of the HIV integrase inhibitor, raltegravir, in cerebrospinal fluid (CSF). This will be accomplished by collecting CSF before and after initiation of either raltegravir or another antiretroviral, efavirenz, each in combination with two other antiretrovirals. Assessments will include HIV RNA levels (viral load), neuropsychological testing, mood assessments, and quality of life assessments.
Primary Outcome
Slope of decline of HIV RNA levels in CSF over time
Interventions
- DRUG Efavirenz
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-12 |
| Phase | NA |
Why NCT01293123 stopped before completion
NCT01293123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Efavirenz is the first listed.
NCT01293123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01293123 about?
NCT01293123 is a clinical study titled "Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals". The primary aim of this study is to determine the effects of the HIV integrase inhibitor, raltegravir, in cerebrospinal fluid (CSF). This will be accomplished by collecting CSF before and after initiation of either raltegravir or another antiretroviral, efavirenz, each in combination with two other ...
What is the current status of trial NCT01293123?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2011-12. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01293123?
The interventions under investigation include: Efavirenz (DRUG), Raltegravir (DRUG).
Who is sponsoring clinical trial NCT01293123?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01293123's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia